Pranlukast

Pranlukast

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	R03DC02 (WHO)
Pharmacokinetic data
Metabolism	Hepatic (mainly CYP3A4)
Elimination half-life	1.5 hours
Identifiers
IUPAC name N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-chromen-8-yl]-4-(4-phenylbutoxy)benzamide
CAS Number	103177-37-3 Y
PubChem CID	4887
DrugBank	DB01411 Y
ChemSpider	4718 Y
UNII	TB8Z891092
ChEMBL	ChEMBL21333 Y
CompTox Dashboard (EPA)	DTXSID3043782
ECHA InfoCard	100.236.084
Chemical and physical data
Formula	C27H23N5O4
Molar mass	481.503 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(c2ccc(OCCCCc1ccccc1)cc2)Nc5cccc3c5O/C(=C\C3=O)c4nnnn4
InChI InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32) Y Key:NBQKINXMPLXUET-UHFFFAOYSA-N Y
(verify)

Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. This drug works similarly to Merck & Co.'s Singulair (montelukast). It is widely used in Japan.

Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. There are several similar medications in the group; all appear to be equally effective.